Malignant gliomas (MGs) are cancers with poor prognosis and limited therapeutic options. Herpes Simplex virus-1 thymidine kinase expressed from adenoviruses with prodrug ganciclovir (TK/GCV) is the best-characterized suicide gene therapy, whereas temozolomide (TMZ) is the first-line chemotherapy for MG. However, the potential of their combination has not been studied thoroughly. The aim of this study was to evaluate the therapeutic response of this combination and to study whether addition of valproic acid (VPA) could benefit the treatment outcome. Efficacies of different treatments were first studied in vitro in BT4C rat MG cells. Therapeutic assessment in vivo was done in an immunocompetent rat MG model for treatment efficacy and toxicity. In vitro, VPA was able to significantly enhance cytotoxicity and increase adenovirus-mediated transduction efficiency up to sevenfold. In vivo, rats receiving TK/GCV þ TMZ had notably smaller tumors and enhanced survival (Po0.001) in comparison with control rats. However, VPA was not able to further enhance the treatment response in vivo. Leukocytopenia and thrombocytopenia were the major side effects. We conclude that careful optimization of the treatment schedules and doses of individual therapies are necessary to achieve an optimal therapeutic effect with TK/GCV þ TMZ combination. No further in vivo benefit with VPA was observed.
INTRODUCTION
Malignant glioma (MG) is a devastating brain cancer with a poor prognosis: patients diagnosed with the most aggressive form of the tumor live B14 months after the diagnosis. 1, 2 Standard care of MG patients with surgery, radiotherapy and chemotherapy leads to poor clinical outcome that is mainly attributed to limitations and inefficiencies of the treatments and is caused by the heterogeneity of tumors. Therefore, there is a need for new treatment modalities. MG is an ideal target for gene therapy because of its local occurrence, rarely metastasizing character and the surrounding environment consisting largely of the nondividing brain parenchyma. 3, 4 Epigenetic mechanisms, such as remodeling of chromatin structure, are important regulators of gene expression. Action of histone acetylases leads to loose, transcriptionally active chromatin. 5 Conversely, actions of histone deacetylases result in condensed and transcriptionally silenced chromatin. Therefore, by blocking actions of histone deacetylases, histone deacetylase inhibitors (HDIs) can cause hyperacetylation of histones and alter gene expression, which has been shown to preferably happen in transformed cells as compared with normal cells. 6, 7 By promoting open chromatin, HDIs permit better access for the DNA damaging agents, in addition to reversing some aberrant epigenetic gene silencing and thus improving therapeutic efficacy. 8 Valproic acid (VPA) is a HDI that belongs to a class of short chain fatty acids. 9 Traditionally, VPA has been used as an anticonvulsant for the epileptic seizures and as a mood-stabilizing drug in bipolar disorders. 10 In addition to its function on lysine residues of histones, it has several properties, which make it an attractive tool to be used with gene therapy. VPA has been shown to enhance transduction efficacy and upregulate transgene expression. 11, 12 Similar HDIs have also been shown to enhance bystander effect by increasing gap junctional communication via increased Connexin 43 expression. 13 Oral alkylating agent temozolomide (TMZ) is currently the first-line clinical chemotherapy for the treatment of MG. VPA has been shown to sensitize glioma cells to TMZ without antagonizing its effect. 14 This synergism is possibly mediated by redox regulation. 15 Furthermore, patients receiving both VPA and TMZ were shown to have an improved survival in EORTC/ NCIC phase III trial. 16 HSV-TK/GCV approach is the most studied and widely used suicide gene therapy approach in cancer including MG. 17 In this study, we wanted to investigate whether addition of VPA into TK/GCV þ TMZ combination would result in a better treatment outcome in terms of controlling tumor growth and survival of rats having MG (Figure 1) . VPA improved the cytotoxicity of TK/GCV þ TMZ and enhanced the transduction efficacy and bystander effect in vitro in rat MG cells. Although the transduction efficiency was increased in vivo, no further treatment benefit was observed when adding VPA into TK/GCV þ TMZ combination in an orthotopic immunocompetent rat MG model. On the basis of our results, we conclude that at least in this experimental setting VPA was not able to bring any further therapeutic benefit when given with TK/GCV and TMZ therapies in vivo. The conventional 14-day GCV treatment after TK gene transfer with a simultaneous 5-day TMZ therapy proved to be superior to the previously tested 7-day GCV treatment protocol.
RESULTS

Enhancement of combination treatment efficacy and transduction efficacy in vitro
Combination of VPA with the TK/GCV and TMZ enhanced the cytotoxicity of both TK/GCV and TMZ alone and in combination in a dose-dependent manner. BT4C cell viability of the control group (GCV-TMZ-), compared with GCV-TMZ þ and GCV þ TMZ þ groups, was statistically better with all VPA doses in both nontransduced and transduced cells, and in GCV þ TMZ-group with VPA doses of 0.5 and 1 mM in transduced cells (Figures 2a and b) . The VPA concentration 0.5-1 mM is close to the therapeutically achievable serum concentrations when VPA is used as an antiepileptic drug. 15 VPA notably enhanced the adenoviral transduction efficacy in a dose-dependent manner. At multiplicity of infection (MOI) 1, VPA enhanced transduction from 3.0% without VPA to 22.2% with 1 mM concentration. Corresponding enhancement at MOI 5 was from 14.6 to 54.9% (Figure 2c ).
Enhancement of bystander effect
In the bystander experiment, VPA was able to potentiate the efficacy of TK/GCV cytotoxicity. VPA or GCV at 1 or 10 mg ml À 1 without TK did not affect the survival of cells (Figure 2d ). At each cell density, the survival of cells when 20% of the cells were TK positive was further decreased by adding VPA into TK/GCV combination. For example, using 2000 cells per well, 1 mg ml À 1 GCV (GCV 1 VPA-) decreased the cell viability to 93% of the control (GCV 0 VPA-), and addition of VPA (GCV 1 VPA þ ) further dropped it to 55%. Corresponding percentages for GCV at 10 mg ml À 1 were 62% (GCV 10 VPA-) and 14% (GCV 10 VPA þ ).
Connexin 43 immunofluorescence staining Effect of VPA on cell junction protein Connexin 43 (Cx43) was assessed on BT4C cell cultures on chamber slides. Addition of VPA resulted in Cx43 localization to the cell junctions. In the absence of VPA, Cx43 was distributed more diffusely in cell cytoplasm and only to a minor extent to cell junctions (Supplementary Figure S1 ).
Evaluation of VPA dosing A preliminary experiment was performed to evaluate the route of delivery and dose of VPA in vivo. After adding VPA into drinking water, rats drank less than normally. 18 When sucrose or Nutrisal were added to cover up the taste of VPA, water consumption was partly regained, but serum VPA levels were low (Supplementary Figure S2a) and water intake was too variable for reliable drug administration. By increasing VPA concentration up to 1500 mg kg À 1 per day in drinking water, serum VPA levels were higher (Supplementary Figure S2b) , but rats drank less and were notably dehydrated with decreased body weight. For a more reliable delivery route, intraperitoneal (i.p.) and subcutaneous (s.c.) dosing of VPA was evaluated. For example, after 200 mg kg À 1 s.c. injection of VPA, corresponding VPA plasma levels were 1100-1200 mM two and half hours after the injection (Supplementary Figure S2c) . However, because of the fast kinetics, serum level had dropped to about one-tenth of this 2 h later. The 500 mg kg À 1 s.c. dosing resulted in plasma VPA concentrations of almost 5000 mM. However, with this dose, although VPA plasma concentrations remained elevated, the rats had to be killed because of the poor well-being.
Administration of VPA before gene transfers was able to enhance overall transduction efficacy in vivo, assessed by betagalactosidase staining of frozen brain sections (data not shown). , and serum VPA levels were checked on days 23 and 30 during the 2-week treatment period. VPA levels were 536-883 mM (n ¼ 3) on day 23 and 96-399 mM (n ¼ 5) on day 30.
Tumor volumes and survival of rats VPA failed to reduce the tumor growth alone or in combination with TMZ, TK þ GCV or TK þ GCV þ TMZ in the BT4C rat MG model ( Figure 3a, Supplementary Figure S3a) . By day 28, none of the combination groups had received TMZ yet. Hence, the impact on the tumor volumes is purely of TK þ GCV. There were no significant differences in the mean tumor volumes among these groups. By day 42, the groups that received TK þ GCV and TMZ had lower mean tumor volumes compared with the TK þ GCV groups, but the results were not statistically significant. However, the differences were significant when compared with the TK þ GCV þ VPA group (Figure 3a ). There were no surviving animals in the control group by this time, and no comparisons were possible with the VPA and TMZ þ VPA groups because of small animal numbers. Combination of TMZ and TK þ GCV enabled to maintain a slower tumor growth rate over a prolonged period of time.
VPA failed to show a survival benefit alone or in combination with TMZ (Supplementary Figure S3b) . However, TK þ GCV þ VPA (Po0.01) and TK þ GCV þ TMZ þ VPA (Po0.001) enhanced the survival significantly compared with the control group (Figures 3b  and c) . Further, TK þ GCV (Po0.05) and TK þ GCV þ TMZ (Po0.001) also enhanced survival compared with the control group.
were not statistically significant. TK þ GCV þ TMZ group had a significantly better survival compared with the TK þ GCV þ VPA (Po0.01) group (Figures 3b and c) . TK þ GCV þ TMZ combination increased the mean survival by 57%, 38%, 33% and 14% compared with the control, TK þ GCV, TK þ GCV þ VPA and TK þ GCV þ TMZ þ VPA groups, respectively. Representative magnetic resonance imaging (MRI) data are shown for corresponding groups (Figure 3d ).
TK þ GCV þ TMZ treatment used in this study (14-day GCV with the last 5 days combined to TMZ) proved to be superior over a previously used protocol, TK þ GCV þ TMZ (gap), where TMZ was not given in combination with GCV (7-day GCV, 5-day gap, 5-day TMZ). Tumors were significantly smaller (Po0.01 at day 42) and survival was better (Po0.05) with TK þ GCV þ TMZ in comparison with TK þ GCV þ TMZ (gap) (Figures 4a and b) .
Blood values TMZ and VPA are known to cause hematological toxicities. 19 To evaluate systemic toxicities of the treatments, blood samples were collected and analyzed 10 days after completing the therapy. All groups that received TMZ had leukocytopenia and thrombocytopenia (Figures 5a and b) . Groups that received VPA had also a tendency for thrombocytopenia, and this effect was more prominent in groups receiving both TMZ and VPA. Thrombocytopenia reached significance compared with the control group in TK þ GCV þ TMZ (Po0.05) as well as TMZ þ VPA and TK þ GCV þ TMZ þ VPA (Po0.01) groups (Figure 5b ). For red blood cells and hemoglobin level, no such changes were observed (data not shown).
DISCUSSION
MGs are aggressive brain cancers with a dismal prognosis. Poor outcome of these patients is largely due to the inefficacy of currently available treatments and the lack of novel therapeutic options. Possible synergistic effect between the current standard chemotherapy for MG, TMZ and the novel experimental therapeutic, adenovirus TK/GCV, has been postulated. Interestingly, VPA, traditionally used as an anticonvulsant, seems to possess diverse properties that may influence the tumors by itself or have an impact on these treatments. VPA is capable of altering the expression of more than 20% of the transcriptome in a tissue-specific manner making it very difficult to anticipate all in vivo effects. 10 VPA-mediated modulations have been implicated in tumor angiogenesis, immunogenicity, invasion, metastasis, differentiation, proliferation and apoptosis. 20 On the other hand, some pro-tumor mechanisms of histone deacetylase inhibitors such as inhibition of druginduced apoptosis 21 and increasing cancer cell motility 20 have also been proposed. In this study, we aimed at delineating an optimal treatment protocol to combine TK/GCV and TMZ that would be compatible in clinical use and to evaluate the impact of VPA on the combination.
Recently, there have been several publications about benefits of VPA as HDI in cancer therapy. However, a lot of these studies have been done in vitro with physiologically unattainable VPA concentrations. 22, 23 It has also been shown that higher VPA concentrations can lead to poor well-being and weight loss of rats. 24 In our in vitro experiments, VPA concentrations (up to 1 mM) were chosen to correspond to achievable serum concentrations. VPA was shown to enhance cell killing and increase transduction efficacy in a dose-dependent manner. Functionality was proven by an enhanced bystander effect and the relocalization of Cx43 to cell junctions following VPA treatment. In our in vivo VPA dosing experiment, concentration of 200 mg kg À 1 was chosen for its sufficient serum concentrations and better tolerability in comparison with higher concentrations evaluated. Because of the fast kinetics, twice-a-day dosing, 12 h apart, was selected to maintain higher VPA serum concentrations in comparison with single dosing. Subcutaneous dosing was adopted because administration in drinking water proved to be unreliable, and rats already received other medications intraperitoneally, namely TMZ and GCV. VPA serum concentrations during the main in vivo experiment varied from 100 to 900 mM, which are in line with serum levels from cancer patients treated with VPA. 25 VPA has been widely used for seizure control in MG patients. 26 It has also been shown to have cell type-specific anticancer properties. 20 HDIs have been successfully used as single-agent therapies in hematological malignancies where dedifferentiation is a primary carcinogenic event and reversible by epigenetic effects of HDI. However, in solid tumors therapeutic success has not been so uniform, 5, 27, 28 although recent data suggest that VPA impairs the expression of DNA repair protein O 6 -methylguanine-DNA methyltransferase and sensitizes MG cells to TMZ. 22 Another study demonstrated that VPA sensitizes MG cells to both TMZ and g-radiation, and, more importantly, VPA did not antagonize the cytotoxicity of TMZ.
14 Evaluation of data from EORTC/NCIC phase III trial has revealed that patients who received both VPA and TMZ had a better survival. However, no general correlation between the use of VPA and survival of MG patients has been reported. 26, 29 On the other hand, no benefit was seen with VPA and RT without TMZ, suggesting that VPA-mediated enhanced efficacy is TMZdependent. 16 Also other studies have failed to demonstrate synergy between VPA and chemotherapy. 23 This was also the case in our in vivo experiments. No further benefit of adding VPA into TK/GCV and TMZ therapy in controlling the rat tumor growth or survival was observed.
One reason for the failure of VPA to enhance the efficacy of TK/GCV and TMZ therapy in vivo could have been the reduced availability of VPA in the target site after s.c. dosing. Evidence suggests that rodents tend to eliminate VPA 10 times faster than humans, elimination time in humans being 9-16 h and in rats less than an hour. 10, 30 In addition, literature suggests that the bioavailability in mice after 80-100 mg kg À 1 i.p. dosing results in plasma and brain concentrations of 120-150 mg ml (830-1040 mM) and 25-40 mg g À 1 (170-280 mM), respectively. In humans, corresponding plasma and brain concentrations after 15-20 mg kg À 1 oral dosing were 40-100 mg ml À 1 (280-690 mM) and 6-27 mg g À 1 (42-190 mM) , respectively. 31 Considering the fast kinetics in rodents, twice-a-day dosing used in our study may not have been frequent enough to maintain the therapeutic concentration over a long period of time, although serum values measured were at the desirable level at the studied time points. In addition to difference in kinetics and biodistribution, lower gene transfer efficacy in vivo in comparison with in vitro may explain the lack of augmentation seen in vivo with VPA. Also, responses to VPA by various cell types in vivo can not be modeled by in vitro culture systems. Interestingly, some of the effects of HDIs have been shown to hamper overall therapeutic response by increasing expression of multi-drug resistance proteins, leading to increased cellular efflux of chemotherapeutic agents. 32, 33 In the rat MG model, TK þ GCV þ TMZ demonstrated the best survival outcome in the entire study and provided clear in vivo evidence, for the first time, of a superior survival benefit compared with either of the therapies given alone. Previous combination studies did not demonstrate a clear in vivo benefit with these two combinations. 34 The 14-day GCV therapy is commonly used in MG patients in clinical trials, 35, 36 and on the basis of findings from the phase III study by Stupp et al.
1 TMZ became the standard adjuvant chemotherapy for glioblastoma multiforme patients. Hence, it would be worthwhile to evaluate the therapeutic benefit of adding TMZ either simultaneously with GCV or immediately after GCV in MG patients. On the basis of current results, this should enhance the efficacy of the treatment combination. In the current study, GCV given for 14 days with TMZ included on the last 5 days proved to significantly improve survival of rats in comparison with the protocol where GCV was given for 7 days followed by a 5-day treatment free gap and a 5-day TMZ period. In the latter protocol, GCV was given only for 7 days because of the limited survival time of rats in this model. TMZ and VPA have been shown to cause hematological toxicity in patients, 19 and therefore full blood cell counts were also analyzed in this study. Both VPA and TMZ were shown to cause thrombocytopenia that was worsen when both drugs were combined. Thrombocytopenia as well as leukocytopenia observed after TMZ treatment were similar to those observed in patients. 16 In conclusion, 14-day GCV treatment after TK gene transfer with a simultaneous 5-day TMZ therapy proved to be superior to the previously tested protocol with a gap between GCV and TMZ administrations. Simultaneous treatment significantly improved the survival of rats and could therefore be of value for MG patients. Addition of VPA into the treatment combination brought no further benefit in this experimental setting.
MATERIALS AND METHODS
Cells, viral vectors and chemicals
BT4C rat MG cells 37 were used in in vitro experiments as well as in rat MG model. Cells were grown in vitro in Dulbecco's modified eagle's medium Figure 4 . Comparison of treatment protocols. Tumor volumes from magnetic resonance imaging (MRI) at day 28 and 42 post inoculation for the control group and TK þ GCV þ TMZ treatment with two separate protocols (a). Survival proportions of corresponding groups in days after tumor inoculation (b). The TK þ GCV þ TMZ group was treated with GCV for 14 days including TMZ on the last 5 days. The TK þ GCV þ TMZ (gap) group (n ¼ 9) received GCV for 7 days followed by a 5-day gap and then TMZ for the 5 following days. Otherwise treatment protocols were the same. Control, non-operated rats; TK, Ad.HSV-TK; GCV, ganciclovir; TMZ, temozolomide; ND, not detected (no survivors left). *Po0.05 and **Po0.01. Error bars ¼ s.e.m. Figure 5 . Blood values. White blood cell (a) and platelet counts (b) analyzed from whole blood samples of rats 10 days after finishing the treatments. Significances compared with the control group are indicated. WBC, white blood cells; PLT, platelets; Control, non-operated rats; TK, Ad.HSV-TK; GCV, ganciclovir; TMZ, temozolomide; VPA, sodium valproate. *Po0.05 and **Po0.01. Error bars ¼ s.e.m.
(DMEM) supplemented with 10% FBS and 1% penicillin-streptomycin. Adenoviral vector Ad.HSV-TK is a serotype 5 adenovirus containing Herpes Simplex virus thymidine kinase (HSV-TK) transgene under cytomegalovirus promoter. 38 Ad.GFP has a green fluorescent protein, and Ad.LacZ beta galactosidase, under the cytomegalovirus promoter. These adenoviral vectors are E1 and partially E3 gene deleted vectors with expression cassette cloned into Bgl II site at Ad0-1 genomic unit location. 35, 36 Adenovirus production was done in HEK293 cells as described previously, 39 and the titers of the viruses were 2.4 Â 10 10 p.f.u. ml À 1 (Ad.HSV-TK), 3.9 Â 10 10 p.f.u. ml À 1 (Ad.GFP) and 2.4 Â 10 10 p.f.u. ml 
Rat MG model
All animal experiments were approved by the Animal Welfare and Ethics Committee of University of Eastern Finland. Immunocompetent, inbred, male BDIX rats (Charles Rivers Laboratories, Lille, France) weighing 175-200 g and bearing orthotopic BT4C rat MGs were created as described elsewhere. 38, 40 Briefly, a total of 10 000 BT4C cells in 5 ml of Optimem medium (Invitrogen, Carlsbad, CA, USA) were slowly injected into the anaesthetized (ketamine and medetomidine) rat brain. Coordinates were 1 mm posterior to the bregma and 2 mm to the right of sagittal suture, 41 at a depth of 2.5 mm (above the right corpus callosum), over 5 min. 27G Hamilton syringe (Hamilton, Bonaduz Ab, Switzerland) mounted to a stereotactic device (David Kopf Instruments, CA, USA) was used. Needle was left in place for 5 min and then slowly withdrawn to avoid backflow.
Intratumoral gene transfers were done on post inoculation (p.i.) days 14 and 15 after confirming the existence of tumors using an MRI on p.i. days 12 and 13. A total volume of 20 ml of Ad.HSV-TK or Ad.LacZ was administered using a Hamilton syringe placed in the stereotactic device. Vector injections of 10 ml were carried out at vertical depths of 2.0 and 2.5 mm from the bregma. Needle was left in place for 5 min at each depth for proper dissipation of the vector solution. Valproate, TMZ and ganciclovir were administered as described above and summarized in Figure 1 . Rats were further imaged with an MRI at days 28 and 42 p.i, and whole blood samples collected 10 days after completing the therapy (Figure 1 ).
MRI and blood sampling
The presence of intracranial tumors was verified at day 12 or 13 p.i. using an MRI. Further MRI follow-ups were done on days 28 and 42 p.i. Anesthesia was induced with 5% isoflurane in a mixture of 70:30% N 2 O:O 2 and was maintained at 1.5% isoflurane. MRIs were done using a 9.4T small animal MRI scanner (Varian Medical Systems, Palo Alto, CA, USA) interfaced to a Varian DirectDrive console as described elsewhere. 42 Blood samples were collected 10 days after completing the treatment for full blood count analysis in order to assess the toxicity of the treatment. Blood samples were analyzed at Movet laboratory (Kuopio, Finland).
Gene transfer efficacy in vivo
To study the effect of VPA on gene transfer efficacy in vivo, six rats received Ad.LacZ gene transfers at days 14 and 15 p.i., as described above. VPA was administered to three preceding gene transfer, and three rats were left untreated. Five days post transduction, rats were killed and brains were frozen in isopentane. All brains were cut into 10 mm sections, and every 10th slice was stained with hematoxylin-eosin for locating the tumors. Consecutive slides were stained enzymatically for beta-galactosidase activity and sections with highest positivity were further imaged with an Olympus AX-70 microscope (Olympus) with the analysis software (Soft Imaging System, Mü nster, Germany) for assessment of effect of VPA on transduction efficacy.
Statistical analysis
Experiments were carried out with three or more replicates. Transduction efficacy measurements in vitro were done in duplicates. Results are expressed as mean ± s.e.m. Statistical analyses were performed with the GraphPad Prism version 5.03 (GraphPad Software, San Diego, CA, USA). Kolmogorov-Smirnov test was used to assess the normality of data. Kruskall-Wallis test, followed by Dunn's multiple comparison post hoc test, was used as a non-parametric test. One way analysis of variance (ANOVA) was used as a parametric test, followed by Bonferroni's multiple comparison test, when relevant. Survival data analysis was done using Kaplan-Meier survival plots, and the survival curves were compared using the Mantel-Cox Log-rank test. P-value o0.05 was considered statistically significant.
